Company intelligence / Profile preview

Temel

Agoura Hills, California, USA

Ownership: Private
Development stage: Other

Overview

Temel is a biotechnology company dedicated to developing transformative therapies for patients with cardiovascular and metabolic diseases. Founded by industry veterans from Akcea Therapeutics and Ionis Pharmaceuticals, the company leverages deep expertise in lipid metabolism and vascular biology to address high-unmet-need conditions. Temel is backed by prominent life science investors including Westlake Village BioPartners and Casdin Capital. The company's mission is to advance a pipeline of novel candidates that target the underlying drivers of heart disease. Currently in the pre-clinical stage, Temel is focused on building a robust portfolio of therapeutic assets through internal research and strategic development.

Therapeutic areas: CardiovascularMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Temel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Temel.

Explore the full profile